The Gegen Qinlian Powder Veterinary Grade API is a spray-dried aqueous extract derived from the four-herb formulation of Puerariae Lobatae Radix, Scutellariae Radix, Coptidis Rhizoma, and Glycyrrhizae Radix et Rhizoma Preparata. The material is standardized by HPLC to total flavonoid and alkaloid markers, with a certificate-of-analysis framework that includes loss on drying ≤ 5.0%, sulfated ash ≤ 6.0%, heavy metal limits of Pb ≤ 5 mg/kg, As ≤ 2 mg/kg, and Cd ≤ 0.5 mg/kg by ICP-MS. The extract contains a maltodextrin carrier fraction of 20–30% w/w and is controlled to D90 ≤ 250 µm for dry blending and D90 ≤ 180 µm for aqueous reconstitution. Supplied in vacuum-sealed 25 kg PE-lined paper bags, the API is sensitive to alkaline pH, prolonged exposure above 70°C, and hygroscopic caking above 60% RH. The following downstream applications address those constraints by dosage form, species, and manufacturing route.

Weaner Piglet Scours and Post-Weaning Enteric Bacterial Challenge Control in Feed-Line Applications

In weaner piglet production, Gegen Qinlian Powder Veterinary Grade API is incorporated as a dry premix or granulated oral product to manage post-weaning enteric bacterial challenge associated with Escherichia coli and Salmonella enterica. The applicable compliance framework includes Chinese Veterinary Pharmacopoeia 2020 for herbal extract identity, purity, and assay; Ministry of Agriculture and Rural Affairs Veterinary Drug GMP 2020 revision for batch release; ISO 22000:2018 for feed-safety prerequisite programs; and ISO/IEC 17025:2017 for finished-premix analytical verification. The addition ratio for a 10:1 aqueous extract is 0.4–1.0 wt% of the final complete feed, while concentrated 5% feed premixes are manufactured with 8–20 wt% API loading. Downstream production begins with pre-blending the spray-dried extract with 0.5 wt% hydrophilic fumed silica and 1.0 wt% calcium silicate to control hygroscopic bridging; the mixture is passed through a 0.8 mm screen before entering a double-ribbon mixer with 1.5 m³ working volume operated at 20–25 rpm for 12–15 min. Homogeneity is verified by 10-point sampling and puerarin assay; the coefficient of variation is held at ≤ 5.0%. Pellet pressing is performed only with low-temperature conditioning at ≤ 60°C and retention time ≤ 30 s, because elevated steam exposure above 70°C reduces total alkaloid recovery and increases batch-to-batch assay drift. Terminal finished product types include 500 g and 5 kg multilayer aluminum pouches for piglet creep feed premix, 2.5 kg HDPE jars of oral granules, and 100 g unit-dose sachets for farrowing-room water medication.

What Limits Re-Solubility and Uniformity in Broiler Drinking-Water Delivery Systems?

Broiler and layer integrations require the API to be formulated as a water-soluble granule or powder for mass medication through nipple or bell drinker lines. The regulatory standards applied to this segment are Chinese Veterinary Pharmacopoeia 2020 for microbial limits and extract assay, VICH GL18(R2) for residual solvent control, EU Regulation 2019/6 where export to European supply chains is involved, and USP <711> dissolution testing for water-dispersible powder. The addition ratio in drinking water is 0.1–0.5 g/L for a 10:1 extract, adjusted to 0.2–0.8 g/L when using granules containing maltodextrin and effervescent carriers. The downstream manufacturing process is built around fluid-bed granulation because dry blending alone produces stratification during transport. A 5.0% aqueous povidone K30 binder is sprayed at 1.2 mm nozzle aperture into a fluid-bed bowl with inlet air at 60–65°C and product temperature at 38–42°C; final granule moisture is controlled to ≤ 4.0%, and the D50 particle size is maintained between 350 µm and 600 µm to guarantee rapid wetting in cold drinking water. The granule matrix includes 0.5–1.0 wt% citric acid to keep reconstituted solution pH at 4.5–5.5, because berberine-type alkaloids precipitate in alkaline hard water and puerarin recovery decreases above pH 7.0. In field water with total hardness above 250 mg/L CaCO₃, a water conditioner is co-packaged at 0.5 wt% of the dose to preserve dissolution; otherwise visible precipitates form within 10 min and line biofilm risk increases. Finished product types in this segment are 100 g and 1 kg water-soluble powder jars, 250 g effervescent tablet tubes, and 5 kg bulk granule pails for farm stock solution tanks.

When a Sterile Parenteral Dosage Form Is Required for Acute Bovine and Ovine Enteric Disease

The injectable route is limited to veterinary hospital administration and uses the water-soluble fraction of the extract after removing high-molecular-weight polysaccharides and potential pyrogens. Compliance for this segment is defined by Chinese Veterinary Pharmacopoeia 2020 injection monograph requirements, USP <71> sterility testing, USP <85> bacterial endotoxin limits, USP <788> subvisible particulate matter, and ICH Q3D elemental impurity risk assessment. The formulation addition ratio is 5–20 mg/mL of the standardized extract reconstituted in Water for Injection; dissolution is achieved at pH 4.5–5.0 with 0.1 M citrate-phosphate buffer, and 2.0% w/v sulfobutylether-β-cyclodextrin is used to suppress berberine precipitation during cold storage. The manufacturing process uses depyrogenated glass containers processed at 250°C for 30 min; the bulk solution is prefiltered through 0.45 µm PVDF, then sterile-filtered through 0.22 µm PVDF membrane capsules into 10 mL or 50 mL amber vials under unidirectional airflow. Terminal sterilization is generally avoided because the total alkaloid and flavonoid markers show measurable loss under 121°C autoclaving; published data for this specific herbal parenteral configuration is limited, so a real-time stability protocol at 5°C ± 3°C must be generated before extended batch release. Terminal finished product types are 10 mL and 50 mL amber borosilicate vials with rubber stoppers and aluminum flip-off seals, supplied with withdrawal-time documentation for food-producing species.

For oral tablet and capsule manufacture intended for calves, lambs, and adult ruminants, the primary process challenge is compressibility of a brittle maltodextrin-based extract. The applicable standards include Chinese Veterinary Pharmacopoeia 2020 tablet and capsule monographs, USP <701> disintegration, USP <905> content uniformity, and USP <467> residual solvent verification. The extract is incorporated at 20–35 wt% of the tablet core and 30–50 wt% of capsule fill; above 35 wt% tablet loading, capping and lamination occur at compression speeds above 30 rpm on single-rotary presses without pre-compression. The downstream process uses high-shear wet granulation with a 5.0% povidone K30 aqueous binder, impeller speed 300 rpm, chopper speed 1500 rpm, and wet massing time of 3–5 min; granules are dried at 50–55°C to ≤ 3.0% moisture and milled through a 1.0 mm screen before blending with crospovidone 3.0 wt% and magnesium stearate 0.5 wt%. Tablets are compressed at 12–18 kN to hardness 70–120 N; disintegration time is maintained below 30 min in 0.1 M HCl at 37°C. Capsule filling uses size 0 or size 1 hard gelatin capsules with the same granulation; flowability is adjusted with 0.5 wt% fumed silica to achieve a Carr index below 25. Terminal products are 500 mg round tablets, 1 g ovoid ruminant boluses, and 250 mg or 500 mg capsules packed in aluminum blisters or HDPE bottles with desiccant.

Acidified oral solutions and drench presentations are manufactured for pre-ruminant calves and lambs when the operator requires a flexible dose by body weight. The compliance structure for this segment is Chinese Veterinary Pharmacopoeia 2020 oral solution requirements, USP <912> oral drug product quality tests, VICH GL18(R2) for residual solvents, and EU Regulation 2019/6 pharmacovigilance reporting when applicable. The API is added at 5–15 wt% of the final solution, dissolved in purified water at 55°C, and stabilized with 0.5–1.0 wt% citric acid anhydrous; pH is maintained at 4.5–5.5 to reduce precipitation of berberine-type alkaloids and to provide a preservative-supportive environment. The production line uses a high-shear homogenizer at 10,000 rpm for 10 min to disperse residual extract agglomerates, followed by plate-and-frame filtration through 5 µm and 1 µm polypropylene membranes. The solution is pasteurized at 65°C for 30 min and filled into light-resistant HDPE bottles; dissolved oxygen is limited to ≤ 1.0 mg/L by nitrogen sparging to reduce oxidative degradation of baicalin. Terminal finished product types include 100 mL, 500 mL, and 1 L calibrated oral drench bottles with polypropylene adapters, plus 10 mL single-use plastic ampoules for lambing barns.

In compound feed premix operations that co-formulate Gegen Qinlian Powder Veterinary Grade API with organic acids and direct-fed microbials, segregation risk and acid-induced caking are the dominant process constraints. The applicable standards are ISO 22000:2018 for feed safety, FAMI-QS certification for specialty feed ingredients, GMP+ B1 for medicated feed additives where applicable, and ISO/IEC 17025:2017 for assay transfer. The final feed addition ratio is 0.3–0.8 wt% for a 10:1 extract; the premix itself is manufactured at 10–15 wt% API loading to fit a 4% final premix. The production process uses sequential addition into a single-shaft paddle mixer with fluidizing baffles; the API is first absorbed onto 2.0 wt% magnesium aluminometasilicate, then the organic acid component is added after 8 min of mixing to localize acid contact. After a further 5 min, a direct-fed microbial component with 1.0 × 10⁹ CFU/g is introduced, and the final mix is discharged at ≤ 6.0% moisture. Packing is performed in 25 kg valve bags with an inner PE barrier layer, and warehousing is maintained at 20–25°C and RH ≤ 60% to prevent extract deliquescence. Terminal products are farm-specific 4% medicated premixes, 25 kg pelleted premix concentrates, and 1 kg diagnostic trial packs for veterinary feed prescription.